CDC 494

Phase:Open Label
Principal Investigator(s):Botswana Ministry of Health, CDC, Gilead
Objective:Follow-on trial of daily oral TDF/FTC in heterosexual men and women.   **Results presented in July 2015 show strong adherence, high drug levels and no HIV infections and support efforts to expand PrEP availability in the context of generalized epidemics in resource-limited settings.**
Prevention Option(s):PrEP
Study Design:
Trial Sponsors: Botswana Ministry of Health, CDC, Gilead
Start Date
End Date
Age range: 18 Years ↔ any
Population:Cisgender Men, Cisgender Women